CLDX: Celldex Therapeutics Inc Company Value to Net Income
Celldex Therapeutics (CLDX) develops advanced monoclonal antibodies to combat cancer and allergies, leveraging robust international logistics chains. The company's P/E fluctuations confirm market expectations, where the -7.80 mark serves as a key metric for valuation analysis. Anthony Marucci's pragmatic approach to clinical trials enables the efficient allocation of resources to advance innovative therapies.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_CLDX_-_Celldex-Therapeutics_-_PE-Multiple "CLDX: Celldex Therapeutics Business Payback Period 07/04/2022 - 11/10/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Celldex (CLDX)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Celldex Therapeutics|CLDX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Celldex Corp|CLDX - Company Debts|Debt to Book Value Ratio Celldex Therapeutics, Inc.|CLDX - Company Long-Term Debts|Short-Term Debt Celldex Therapeutics|Quick Liquidity Indicator celldex.com
- earnings and market multiples details:
CLDX - Net Profit|Expected Net Profit Celldex Therapeutics|CLDX - Price to Earnings Ratio|Future Price to Earnings Celldex Therapeutics Inc|CLDX - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Celldex Therapeutics, Inc.|CLDX - Operating profit EBITDA|Earnings per share for the last 12 months Celldex Therapeutics|CLDX - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months celldex.com|CLDX - Net earnings per share growth this year|Projected earnings per share growth rate for next year Celldex Therapeutics
Comprehensive company analysis:celldex.com CLDX
The specific nature of Celldex Therapeutics (CLDX) as a clinical developer makes its revenues dependent on regulatory decisions, transforming classic earnings valuation into a risk analysis tool. By analyzing the company's current P/E, an investor determines the payback period of the market value through net income, identifying overpayments or speculative capitalization premiums amid the high cash flow uncertainty characteristic of the biotech sector.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio AUPH|P/E Multiple BioCryst Corp|Price to Earnings Ratio Vera Therapeutics, Inc. (VERA)|dianthustx.com - Price to Earnings Multiple|P/E Multiple PHVS (Pharvaris)|AbCellera Corp (ABCL) - Market Cap to Earnings|Tourmaline Corp - P/E Multiple|Precigen Corp (PGEN) - Price to Earnings Ratio|PHAR: P/E Multiple|Market Cap to Earnings nektar.com (NKTR)|Price to Earnings Ratio Upstream Bio|Price to Earnings Ratio ZBIO|Price to Earnings Ratio Immunome Corp (IMNM)|Price to Earnings Ratio GOSS (Gossamer Bio Corp.)|P/E Multiple KALV (KalVista Pharmaceuticals)|SEPN: Price to Earnings Multiple|Pieris Pharmaceuticals, Inc. - P/E Multiple|Market Cap to Earnings Savara Inc|RIGL (Rigel Pharmaceuticals Inc) - Price to Earnings Ratio|Price to Earnings Multiple ANAB|Price to Earnings Ratio ATXS|ENGN: Company Value to Net Income|Price to Earnings Ratio RAPT (RAPT Therapeutics)|Market Price to Net Income Ratio JBIO|P/E Multiple ACRS (Aclaris)|Company Value to Net Income KYTX|Tiziana Life Sciences - P/E Multiple|Market Cap to Earnings cabalettabio.com|Ventyx Biosciences, Inc. (VTYX) - Price to Earnings Ratio|Theratechnologies, Inc. - Company Value to Net Income|AVTX (Avalo Therapeutics Inc.) - P/E Multiple|P/E Multiple Eledon Pharmaceuticals, Inc|Price to Earnings Ratio Agenus (AGEN)|CLYM: Market Cap to Net Income|P/E Multiple ZURA (Zura Bio)|aTyr Pharma Inc (ATYR) - Market Cap to Earnings|ADAG: Price to Earnings Ratio|IMA - P/E Multiple|STTK (shattucklabs.com) - Price to Earnings Ratio|EQ: Market Price to Net Income Ratio|CNTB (Connect Biopharma Holdings) - P/E Multiple|Immunic Inc (IMUX) - Business Payback Period|P/E Multiple ATRA|Price to Earnings Ratio inflarx.de IFRX|Price to Earnings Ratio X4 Pharmaceuticals XFOR|Business Payback Period Adicet Bio Inc. (ACET)|Celularity Corp - P/E Multiple|INmune Bio Inc (INMB) - Price to Earnings Ratio|Barinthus Bio (BRNS) - Price to Earnings Ratio|KZR (Kezar Life Sciences Inc) - Price to Earnings Ratio|SABS (SAB Biotherapeutics) - P/E Multiple|Price to Earnings Multiple AKTX (akaritx.com)|Price to Earnings Ratio ENLV (Enlivex Therapeutics)|q32bio.com - Price to Earnings Multiple|Price to Earnings Ratio GeoVax Labs Inc GOVX|EDSA (Edesa Biotech Corp) - Market Cap to Net Income|iBio, Inc. - P/E Multiple|Company Value to Net Income CARM (Carisma Therapeutics)|XTLB: P/E Multiple|Bolt Biotherapeutics, Inc. (BOLT) - P/E Multiple|Price to Earnings Ratio HCW Biologics, Inc.|APVO: Company Value to Net Income|Price to Earnings Ratio AIM ImmunoTech Inc. (AIM)|Price to Earnings Ratio aditxt.com ADTX|P/E Multiple GRI (GRI Bio)|P/E Multiple XORTX Therapeutics Inc XRTX|HIND: Price to Earnings Ratio|Company Value to Net Income REVB (Revelation Biosciences Corp)|INDP: P/E Multiple|SCNI - Business Payback Period|Price to Earnings Ratio CalciMedica Inc|Price to Earnings Ratio Affimed Therapeutics (AFMD)|Price to Earnings Ratio Allakos Inc. (ALLK)|Price to Earnings Ratio hookipapharma.com HOOK|IGM Biosciences - Price to Earnings Ratio|P/E Multiple iteostherapeutics.com ITOS|OCEA - Price to Earnings Ratio|TCBP (TC BioPharm (Holdings) Plc) - Price to Earnings Multiple|THRD: P/E Multiple
